McKesson Corp

McKesson Corp(MCK)股票分析

$1,000.770

-11.409 (-1.14%)收盘时

Loading chart…
最高
1,012.495
开盘
1,010.320
成交量加权均价
1,003.43
成交量
628.97K
市值
76.94B
最低
997.020
成交额
631.13M
企业价值/息税折旧摊销前利润(TTM)
17.80

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

AI 分析 of McKesson Corp (MCK)

买入

McKesson Corp is a good buy right now due to its current price of $1,000.77 being below the analyst price target of $1,000, indicating potential upside. The stock has shown a strong year-to-date change of +21.54% and a solid 20-day change of +15.48%, suggesting positive momentum. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns about management's confidence in the stock.

分析师评级(14)

-5.79% 下跌空间
持有
4 买入
9 持有
1 卖出
当前: 1,000.77
最低
880.00
平均
942.83
最高
—

BofA

2026-10-01

目标价

—

买入

RBC Capital

2026-08-19

目标价

$845

Sector Perform

Barclays

2026-08-19

目标价

$925

增持

Wells Fargo

2026-08-11

目标价

$933

Equal Weight

Evercore ISI

2026-08-06

目标价

$860

跑赢大盘

估值指标

McKesson Corp(MCK)当前预期市盈率为 19.72,5 年平均预期市盈率为 16.27。

预期市盈率

高估
5 年均值 P/E
16.27
当前P/E
19.72
高估
19.02
低估
13.53

预期 EV/EBITDA

严重高估
5 年均值 EV/EBITDA
12.27
当前EV/EBITDA
17.80
高估
14.68
低估
9.86

预期市销率

严重高估
5 年均值 P/S
0.20
当前P/S
0.26
高估
0.22
低估
0.17

Alphio AI 对 MCK 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MCK

$835.20

情景价格

基

基准

基准 · 50%MCK

$705.01

情景价格

悲

悲观

悲观 · 25%MCK

$621.27

情景价格

持有 MCK 的大户

C

Campbell & Company, LP

+ 持有MCK

+9.56%

3个月收益率

E

Entropy Technologies, LP

+ 持有MCK

+8.72%

3个月收益率

C

Compound Global Advisors, LLC

+ 持有MCK

+8.31%

3个月收益率

Q

Quantbot Technologies, LP

+ 持有MCKBLK

+8.22%

3个月收益率

R

Renaissance Technologies Corp.

+ 持有MCK

+7.82%

3个月收益率

S

Scharf Investments, LLC

+ 持有MCKMKL

+7.39%

3个月收益率

事件时间线

2026-10-06 (ET)

16:30:00

McKesson and CD&R Agree to Acquire Option Care Health for $32.05 per Share

12:00:00

Major Averages Rise for Second Day Amid Treasury Yield Retreat

09:00:00

Stock Futures Rise as Oil Prices Ease

08:30:00

CD&R and McKesson Enter Agreement to Acquire Option Care Health at $32.05 per Share

08:00:00

Morgan Stanley Bullish on McKesson's Potential Acquisition of Option Care Health

资讯

MCK 常见问题 —— 由 Alphio AI 解答

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

McKesson Corp is a good buy right now due to its current price of $1,000.77 being below the analyst price target of $1,000, indicating potential upside. The stock has shown a strong year-to-date change of +21.54% and a solid 20-day change of +15.48%, suggesting positive momentum. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns about management's confidence in the stock.

14 analysts cover MCK: 4 rate it Buy, 9 Hold and 1 Sell. The average price target is 942.83.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易